Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells $229,083.25 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 7,573 shares of Hims & Hers Health stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total value of $229,083.25. Following the transaction, the insider owned 11,280 shares in the company, valued at $341,220. This trade represents a 40.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Irene Becklund also recently made the following trade(s):

• On Wednesday, June 17th, Irene Becklund sold 4,490 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.50, for a total value of $141,435.00.

Hims & Hers Health Stock Down 0.1%

NYSE HIMS opened at $35.44 on Friday. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $8.20 billion, a P/E ratio of -393.79, a price-to-earnings-growth ratio of 50.70 and a beta of 2.37. The stock’s 50-day moving average price is $26.74 and its 200-day moving average price is $26.64.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 earnings per share. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.05 earnings per share for the current year.

Wall Street Analyst Weigh In

HIMS has been the topic of several recent analyst reports. Zacks Research downgraded shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, June 8th. Bank of America dropped their target price on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Tuesday, May 26th. TD Cowen cut their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research note on Friday, March 27th. Needham & Company LLC raised their price target on Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Finally, Morgan Stanley lowered their price objective on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $29.37.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the stock. Farallon Capital Management LLC grew its stake in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares in the last quarter. BIT Capital GmbH lifted its stake in Hims & Hers Health by 73.8% in the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after purchasing an additional 938,728 shares in the last quarter. SG Americas Securities LLC lifted its stake in Hims & Hers Health by 25.6% in the 4th quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock worth $12,064,000 after purchasing an additional 75,679 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Finally, CI Investments Inc. boosted its holdings in shares of Hims & Hers Health by 6,659.7% during the 3rd quarter. CI Investments Inc. now owns 206,510 shares of the company’s stock valued at $11,713,000 after purchasing an additional 203,455 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.